Chiauranib
Paclitaxel
Chipscreen Biosciences, Ltd.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Paclitaxel cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
D-thioctic acid Ain Shams University | Phase 4 | BB |
DL-6,8-THIOCTIC ACID Ain Shams University | Phase 4 | BB |
Carboplatin AstraZeneca | Phase 1 | CC |
Olaparib AstraZeneca | Phase 1 | CC |
CIS-DIAMMINEDICHLOROPLATINUM II Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 | CC |
Same molecule, other indications
Chiauranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →